Fujifilm Invests USD 200 Million to Expand Global Cell Therapy CDMO Capabilities

Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Comments are welcome to point out any issues. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.

FUJIFILM Corporation Announces $200 Million Investment in Two Subsidiaries, to significantly expand global cell therapy contract development and manufacturing (CDMO) capabilities. The cell therapy market is expected to grow from $3.3 billion in fiscal 2022 to over 30% annually.

FUJIFILM Corporation is a global leader in the development and manufacturing of human induced pluripotent stem cells (iPSC) and iPSC-derived cells, with a $200 million investment specifically allocated toNew Headquarters of FUJIFILM Cellular Dynamics, a Global Leader in the Development and Manufacturing of Human Induced Pluripotent Stem Cells (iPSC) and iPSC-Derived CellsAndWorld-leading CDMO for Biologics and Advanced TherapiesFUJIFILM Diosynth BiotechnologIES'sCalifornia Plant. 

This investment will provide forFUJIFILM Cellular DynamicsFunding for the newly built 175,000-square-foot headquarters in Madison, Wisconsin, U.S., the new campus will house an iPSC cGMP manufacturing facility, including three cleanrooms, process development laboratories, warehousing operations, and administrative spaces.This investment will double the company's existing production capacity for developing and commercializing iPSC-derived cell therapies for its partners.The new facility will also include iPSC production for drug discovery, drug efficacy, and pharmacology R&D applications. The entire production base, including cell therapy manufacturing, is scheduled to commence operations in the spring of 2026.

FUJIFILM Diosynth Biotechnologies PlantLocated in Thousand Oaks, California, it is a major cluster adjacent to pharmaceutical, biotechnology, and venture capital companies.This investment will provide funding for the expansion of the production base., including a new development lab and two new independent production cleanrooms, significantly boosting the production capacity for new customer projects. The talent at the California production base has extensive experience in the clinical and commercial production of in vitro cell lines, capable of manufacturing for various cell therapies. The additional capacity will be operational by early 2025.